Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1988 Feb;57(2):190–192. doi: 10.1038/bjc.1988.40

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.

M Dowsett 1, R J Shearer 1, B A Ponder 1, P Malone 1, S L Jeffcoate 1
PMCID: PMC2246426  PMID: 3358910

Abstract

Aminoglutethimide has been used in combination with hydrocortisone in patients with advanced prostatic cancer with the rationale that it causes a 'medical adrenalectomy'. Both objective and subjective responses have been recorded. We have examined the effect of AG and HC alone and in combination on plasma androgen levels throughout the day in two studies on 11 such patients. Whilst AG combined with HC led to a significant suppression of both testosterone and androstenedione levels, the suppression with HC alone was significantly greater, indicating that any beneficial clinical effects of AG in these patients is not due to its suppression of adrenal androgen secretion.

Full text

PDF
190

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BURT F. B., FINNEY R. P., SCOTT W. W. Steroid response to therapy in prostatic cancer. J Urol. 1957 Mar;77(3):485–491. doi: 10.1016/S0022-5347(17)66589-3. [DOI] [PubMed] [Google Scholar]
  2. Dexter R. N., Fishman L. M., Ney R. L., Liddle G. W. Inhibition of adrenal corticosteroid synthesis by aminoglutethimide: studies of the mechanism of action. J Clin Endocrinol Metab. 1967 Apr;27(4):473–480. doi: 10.1210/jcem-27-4-473. [DOI] [PubMed] [Google Scholar]
  3. Dowsett M., Harris A. L., Smith I. E., Jeffcoate S. L. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. J Clin Endocrinol Metab. 1984 Jan;58(1):99–104. doi: 10.1210/jcem-58-1-99. [DOI] [PubMed] [Google Scholar]
  4. Drago J. R., Santen R. J., Lipton A., Worgul T. J., Harvey H. A., Boucher A., Manni A., Rohner T. J. Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma. Cancer. 1984 Apr 1;53(7):1447–1450. doi: 10.1002/1097-0142(19840401)53:7<1447::aid-cncr2820530703>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  5. Harris A. L., Dowsett M., Jeffcoate S. L., McKinna J. A., Morgan M., Smith I. E. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab. 1982 Oct;55(4):718–722. doi: 10.1210/jcem-55-4-718. [DOI] [PubMed] [Google Scholar]
  6. Harris A. L., Dowsett M., Smith I. E., Jeffcoate S. L. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer. 1983 May;47(5):621–627. doi: 10.1038/bjc.1983.100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Harris A. L., Dowsett M., Smith I. E., Jeffcoate S. Hydrocortisone alone vs hydrocortisone plus aminoglutethimide: a comparison of the endocrine effects in postmenopausal breast cancer. Eur J Cancer Clin Oncol. 1984 Apr;20(4):463–469. doi: 10.1016/0277-5379(84)90230-x. [DOI] [PubMed] [Google Scholar]
  8. Harris A. L., Mitchell M. D., Smith I. E., Powles T. J. Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer. Br J Cancer. 1983 Oct;48(4):595–598. doi: 10.1038/bjc.1983.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Henderson D., Habenicht U. F., Nishino Y., Kerb U., el Etreby M. F. Aromatase inhibitors and benign prostatic hyperplasia. J Steroid Biochem. 1986 Nov;25(5B):867–876. doi: 10.1016/0022-4731(86)90318-3. [DOI] [PubMed] [Google Scholar]
  10. MILLER G. M., HINMAN F., Jr Cortisone treatment in advanced carcinoma of the prostate. J Urol. 1954 Sep;72(3):485–496. doi: 10.1016/S0022-5347(17)67614-6. [DOI] [PubMed] [Google Scholar]
  11. Plowman P. N., Perry L. A., Chard T. Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. Br J Urol. 1987 Mar;59(3):255–257. doi: 10.1111/j.1464-410x.1987.tb04617.x. [DOI] [PubMed] [Google Scholar]
  12. Ponder B. A., Shearer R. J., Pocock R. D., Miller J., Easton D., Chilvers C. E., Dowsett M., Jeffcoate S. L. Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. Br J Cancer. 1984 Dec;50(6):757–763. doi: 10.1038/bjc.1984.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Robinson M. R., Shearer R. J., Fergusson J. D. Adrenal suppression in the treatment of carcinoma of the prostate. Br J Urol. 1974 Oct;46(5):555–559. doi: 10.1111/j.1464-410x.1974.tb03856.x. [DOI] [PubMed] [Google Scholar]
  14. Rostom A. Y., Folkes A., Lord C., Notley R. G., Schweitzer F. A., White W. F. Aminoglutethimide therapy for advanced carcinoma of the prostate. Br J Urol. 1982 Oct;54(5):552–555. doi: 10.1111/j.1464-410x.1982.tb13589.x. [DOI] [PubMed] [Google Scholar]
  15. Samojlik E., Veldhuis J. D., Wells S. A., Santen R. J. Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma. J Clin Invest. 1980 Mar;65(3):602–612. doi: 10.1172/JCI109705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Santen R. J., Lipton A., Kendall J. Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism. JAMA. 1974 Dec 23;230(12):1661–1665. [PubMed] [Google Scholar]
  17. Santen R. J., Santner S., Davis B., Veldhuis J., Samojlik E., Ruby E. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab. 1978 Dec;47(6):1257–1265. doi: 10.1210/jcem-47-6-1257. [DOI] [PubMed] [Google Scholar]
  18. Schweikert H. U. Conversion of androstenedione to estrone in human fibroblasts cultured from prostate, genital and nongenital skin. Horm Metab Res. 1979 Nov;11(11):635–640. doi: 10.1055/s-0028-1092791. [DOI] [PubMed] [Google Scholar]
  19. Stuart-Harris R., Dowsett M., D'Souza A., Donaldson A., Harris A. L., Jeffcoate S. L., Smith I. E. Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer. Clin Endocrinol (Oxf) 1985 Feb;22(2):219–226. doi: 10.1111/j.1365-2265.1985.tb01083.x. [DOI] [PubMed] [Google Scholar]
  20. Vermeulen A., Paridaens R., Heuson J. C. Effects of aminoglutethimide on adrenal steroid secretion. Clin Endocrinol (Oxf) 1983 Dec;19(6):673–682. doi: 10.1111/j.1365-2265.1983.tb00044.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES